Yonsei Med J.  2010 Jan;51(1):111-116. 10.3349/ymj.2010.51.1.111.

In-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains

• Dundar D
• Otkun M

• KMID: 1779615
• DOI: http://doi.org/10.3349/ymj.2010.51.1.111

Abstract

PURPOSE
Combination antibiotic treatment is preferred in nosocomial infections caused by Pseudomonas aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in clinic. The aim of this study was to investigate the synergistic efficacy of synergistic antibiotic combinations in multidrug resistant P. aeruginosa strains. MATERIALS AND METHODS: Synergistic efficacies of ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-isepamycin, imipenem-ciprofloxacin and ciprofloxacin-tobramycin combinations were investigated by checkerboard technique in 12 multiple-resistant and 13 susceptible P. aeruginosa strains. RESULTS: The ratios of synergy were observed in ceftazidime-tobramycin and piperacillin/tazobactam-tobramycin combinations as 67%, and 50%, respectively, in resistant strains, whereas synergy was not detected in other combinations. The ratios of synergy were observed in ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-ciprofloxacin and imipenem-isepamycin combinations as 31%, 46%, 15%, 8%, 8%, and respectively, in susceptible strains, whereas synergy was not detected in ciprofloxacin-tobramycin combination. Antagonism was not observed in any of the combinations. CONCLUSION: Although the synergistic ratios were high in combinations with ceftazidime or piperacillin/tazobactam and tobramycin, the concentrations in these combinations could not usually reach clinically available levels. Thus, the solution of the problems caused by multiple resistant P. aeruginosa should be based on the prevention of the development of resistance and spread of the causative agent between patients.

Keyword

Pseudomonas aeruginosa; synergy; antimicrobial; combination

MeSH Terms

Anti-Bacterial Agents/*pharmacology
Ceftazidime/pharmacology
Ciprofloxacin/pharmacology
Drug Resistance, Multiple, Bacterial/*drug effects
Drug Synergism
Imipenem/pharmacology
Microbial Sensitivity Tests
Penicillanic Acid/analogs & derivatives/pharmacology
Piperacillin/pharmacology
Pseudomonas aeruginosa/*drug effects
Tobramycin/pharmacology

Reference

1. Pier GB, Ramphal R. Mandell GL, Bennet JE, Dolin R, editors. Pseudomonas aeruginosa. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2005. Volume 2:6 th edition. Philadelphia: Churchill Livingstone;2587–2615.

2. Clinical and laboratory standards institute. Performance standards for antimicrobial disk susceptibility tests. 2006. CLSI Document M2-A9 9th edition. Wayne, PA, USA: CLSI.

3. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. 2006. CLSI Document M100-S16 16th edition. Wayne, PA, USA: CLSI.

4. Barry AL, Thornsberry C, Jones RN, Gerlach EH. Interpretive standards for disk susceptibility tests with Sch21420 and amikacin. Antimicrob Agent Chemother. 1980. 18:616–621.

5. Clinical and laboratory standards institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2003. CLSI Document M7A6 6th edition. Wayne, PA, USA: CLSI.

6. Moody JA, Knapp C. Isenber HD, editor. Tests to assess bactericidal acivity. Clincal microbiology procedures handbook. 2004. Volume 2:2nd edition. Washington: ASM Press;5.10.1.1–5.10.1.17.

7. Moody J. Isenber HD, editor. Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. Clincal microbiology procedures handbook. 2004. Volume 2:2nd edition. Washington: ASM Press;5.12.1–5.12.23.

8. Eliopoulos GM, Moellering RC JR. Lorian V, editor. Antimicrobial Combinations. Antibiotics in Laboratory Medicine. 1996. 4 th edition. Baltimore: Williams & Wilkins;330–396.

9. Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. Diagn Microbiol Infect Dis. 2003. 47:547–550.

10. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med. 1986. 80:126–137.

11. Weiss K, Lapointe JR. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agent Chemother. 1995. 39:2411–2414.

12. Owens RC JR, Banevicius MA, Nicolau DP, Nightingale CH, Quintillani R. In vitro synergistic activities of tobramycine and selected beta-lactams against 75 gram-negative clinical isolates. Antimicrob Agent Chemother. 1997. 41:2586–2588.

13. Chan EL, Zabransky RJ. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis. 1987. 6:157–164.

14. Baltch AL, Bassey C, Hammer MC, Smith RP, Conroy JV, Michelsen PB. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 1991. 27:801–808.

15. Perea EJ, Nogales MC, Aznar J, Martin E, Iglesias MC. Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa. J Antimicrob Chemother. 1980. 6:471–477.

16. Oie S, Sawa A, Kamiya A, Mizuno H. In vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 1999. 44:689–691.

17. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 1997. 29:81–86.

18. Clark RB, Pakiz CB, Hostetter MK. Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram. Med Microbiol Immunol. 1990. 179:77–86.

19. Gerçeker AA, Gürler B. In vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother. 1995. 36:707–711.

20. Bustamante CI, Drusano GL, Wharton RC, Wade JC. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agent Chemother. 1987. 31:632–634.

21. Gould IM, Milne K. In vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother. 1997. 39:53–61.

22. Laverdière M, Gallimore B, Restieri C, Poonia K, Chow AW. In vitro synergism of ceftriaxone combined with aminoglicosides against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 1994. 19:39–46.

23. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1997. 41:95–100.

24. Jones RN, Johnson DM, Barrett MS, Erwin ME. Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. J Chemother. 1991. 3:289–294.

25. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginsa. Int J Antimicrob Agents. 2003. 1:8–12.

26. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin and travofloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis. 2000. 38:37–41.

27. Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin and travafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. Diagn Microbiol Infect Dis. 1999. 33:81–86.

28. Neu HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis. 1991. 10:255–261.

29. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 2002. 50:1045–1049.

30. Drago L, De Vechi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy. 2004. 50:202–210.

31. Mayer I, Nagy E. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother. 1999. 43:651–657.

32. Andes DR, Craig WA. Mandell GL, Bennet JE, Dolin R, editors. Cephalosporins. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2005. Volume 1:6 th edition. Philadelphia: Churchill Livingstone;294–311.

33. Gilbert DN. Mandell GL, Bennet JE, Dolin R, editors. Aminoglycosides. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2005. Volume 1:6 th edition. Philadelphia: Churchill Livingstone;328–356.

34. Perry CM, Markham A. Piperasillin/tazobactam an updated review of its use in the treatment of bacterial infections. Drugs. 1999. 57:805–843.